Key takeaways
- Reviews group skincare peptides into four types: signal, carrier, neurotransmitter-inhibitor and enzyme-inhibitor peptides.
- Well-known examples are palmitoyl pentapeptide-4 (pal-KTTKS), copper tripeptide-1 (GHK-Cu) and acetyl hexapeptide-8.
- Many trials are small and short and measure appearance; a 2026 meta-analysis of 19 randomised trials included only two of peptides applied to the skin.
- How far these peptides get into the skin is uncertain: a 2025 review says acetyl hexapeptide-8 faces limited permeability through the skin’s outer layer.
- In the US, cosmetics need no FDA approval before sale, but a claim to affect the body’s structure or function makes a product a drug.
01The four types of skincare peptide
A 2009 review sorted the peptides used on ageing skin into four groups. Later reviews still use them. Each group is defined by what the peptide was designed to do, not by what trials showed.
| Type | Designed to | Example (ingredient name) | Human trials we cite |
|---|---|---|---|
| Signal peptides | Act as a signal to skin cells (fibroblasts) to make structural proteins such as collagen | Palmitoyl pentapeptide-4 (pal-KTTKS) | One randomised split-face trial, 93 women, 12 weeks (2005) |
| Carrier peptides | Carry substances skin cells use, such as copper | Copper tripeptide-1 (GHK-Cu) | Small studies, mostly conference reports; see topical GHK-Cu |
| Neurotransmitter-inhibitor peptides | Mimic part of SNAP-25, a protein nerve endings use to release signals to muscle | Acetyl hexapeptide-8 | One randomised placebo-controlled trial, 60 adults, 4 weeks (2013) |
| Enzyme-inhibitor peptides | Slow enzymes such as matrix metalloproteinases (MMPs), which break down skin’s structural proteins | Dipeptide-2, tripeptide-2 | Not covered by the trials on this page |
Names matter here. Pal-KTTKS is the palmitoyl form of the five-amino-acid peptide KTTKS, also called pentapeptide-4; the palmitoyl form is sold under the trade name Matrixyl. Acetyl hexapeptide-8 is sold as Argireline. A 2026 review warns that a defined peptide such as palmitoyl pentapeptide-4 “should not be equated with hydrolyzed collagen or a placenta-derived peptide mixture.” Collagen supplements are a separate topic: collagen peptides vs research peptides.
02What the human trials measured
Cosmetic trials measure how skin looks. Here are three, with their design and who ran them.
Palmitoyl pentapeptide-4, 2005. In a trial run at Procter & Gamble, 93 women aged 35 to 55 used a moisturiser with pal-KTTKS on one side of the face and the same moisturiser without it on the other, for 12 weeks. It was double-blind and randomised, and the outcome was wrinkles and fine lines measured in facial images. It is one industry-run trial.
Acetyl hexapeptide-8, 2013. Researchers at a hospital in Xi’an, China, randomised 60 adults, three to one, to acetyl hexapeptide-8 or placebo on the wrinkles around the eyes for 4 weeks. They graded the lines by eye and measured skin roughness from silicone casts of the skin.
Copper tripeptide-1 (GHK-Cu), 2006. After laser resurfacing around the mouth, patients were randomised to skin-care regimens with or without GHK-Cu; 13 completed. Computer analysis and blinded evaluators found no significant difference in redness, wrinkles or overall skin quality, though patients using GHK-Cu products rated their skin quality higher. The other GHK-Cu skin studies are mostly conference reports: topical GHK-Cu lists them.
03Do peptides in skincare work?
The best summary we found says the evidence for peptides applied to the skin is thin.
A 2026 systematic review and meta-analysis pooled 19 randomised trials with 1,341 participants. Seventeen tested peptides taken by mouth; only two tested peptides applied to the skin. The authors write that the wrinkle effect they found was “largely attributable to oral formulations, whereas topical formulations showed limited impact”, and that the imbalance between the two routes constrains definitive conclusions. Products taken by mouth are not skincare, so the pooled result says little about creams.
A 2026 narrative review of peptides in aesthetic dermatology, covering topical and oral products, weighed the controlled human studies and found that “many trials are limited by small samples, short follow-up, industry sponsorship, or multi-ingredient formulations”, and that the evidence supports “product-specific interpretation rather than interchangeability across peptide classes or administration routes.” In plain terms: a trial of one peptide in one cream tells you about that cream, not about peptides in general.
Getting into the skin is part of the problem. A 2025 review of acetyl hexapeptide-8 says that, because it is water-loving and relatively large, it “faces limited permeability through the lipophilic stratum corneum”, the skin’s outer layer, and that its ability to reach the junctions between nerves and muscles “remains uncertain”.
04How skincare peptides are regulated
Each market defines a cosmetic by what it is for. Here is what that means for a peptide cream.
| Market | Before sale | Where the line is |
|---|---|---|
| United States (FDA) | No approval: “cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market.” Since the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), facilities register, products are listed with their ingredients, and serious adverse events must be reported within 15 business days, with exemptions for some small businesses. | Intended use decides. A product “intended to affect the structure or any function of the body” is a drug; FDA’s examples of drug claims include promises to “regenerate cells”. |
| European Union (Regulation 1223/2009) | A named “responsible person” must have the product safety-assessed and notify it to the European Commission before it goes on the market, and keep a product information file with “proof of the effect claimed” where justified. | A cosmetic is placed on external parts of the body, the teeth or the lining of the mouth “with a view exclusively or mainly” to cleaning, perfuming, changing appearance, protecting, keeping in good condition or correcting body odours. Claims “shall not be used to imply that these products have characteristics or functions which they do not have.” |
| Great Britain (OPSS) | The same regulation as amended after Brexit: a responsible person with a UK address, a safety assessment by a qualified assessor, and notification to the Office for Product Safety and Standards before sale. | The responsible person must “be able to prove that any claims made when marketing the product are correct.” |
| Australia | Cosmetic ingredients can be industrial chemicals, regulated by the Australian Industrial Chemicals Introduction Scheme. | The Industrial Chemicals Act 2019 defines a cosmetic by appearance-type purposes and excludes “a therapeutic good within the meaning of the Therapeutic Goods Act 1989”. |
None of the rules we read requires a regulator to check, before sale, that a cream works. The EU and GB require evidence for a product’s claimed effects to be kept on file (in the EU, where the effect justifies it); the US relies on intended use and enforcement. How cosmetic peptides differ from medicines and research compounds: types of peptides.
05What we don’t know
- How much of a peptide in a cream reaches living skin cells in people. The reviews we cite call skin penetration a central limit.
- Whether results for one product apply to another with the same peptide. Formulations, strengths and the other ingredients differ.
- What topical peptides do over years. The trials we cite lasted 4 to 12 weeks.
- How much of the evidence would survive independent replication. Many trials are small and industry-sponsored.
For the copper peptide in detail, see the GHK-Cu research guide and skin research.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.